Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/10495/40144
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorAmariles Muñoz, Pedro-
dc.contributor.authorCano Paniagua, Alejandra-
dc.contributor.authorRestrepo Garay, Margarita María-
dc.contributor.authorAngulo, Nancy-
dc.date.accessioned2024-06-19T14:44:38Z-
dc.date.available2024-06-19T14:44:38Z-
dc.date.issued2019-
dc.identifier.issn1665-2681-
dc.identifier.urihttps://hdl.handle.net/10495/40144-
dc.description.abstractABSTRACT: Introduction and aim: Epidemiological information regarding drug-induced liver injury in some Latin American countries remains limited. Therefore, disease prevention and health promotion strategies are imperative to reduce drug-induced liver injuries and its fatal outcomes. This study aimed to collect epidemiological data regarding drug-induced liver injury and identify associated factors in patients admitted to a university hospital in Colombia. Methods and patients: A prospective study was conducted for 1 year to assess the incidence of druginduced liver injury in patients aged >18 years who showed elevated values in liver tests. Data were collected after obtaining informed consentfrom the patients. The updated Roussel Uclaf Causality Assessment Method was applied to assess the causality of drug-induced liver injury. Results: The study included 286 patients with elevated values in liver tests, 18 of whom presented with drug-induced liver injury. The mean age of patients was 54.7 ± 19.1 years. The associated pharmacological groups were anti-infectives and anticonvulsants (isoniazid, rifampicin, nitrofurantoin, phenytoin, and valproic acid), with a total of 15 drugs. The affected patients presented with cytopenia, jaundice, nausea, vomiting, or hepatomegaly. The most common type of liver injury was hepatocellular, and most patients recovered satisfactorily. The number of patients who had highly probable and probable causality grading was 1 and 9, respectively. Conclusion: The incidence of drug-induced liver injury in a university hospital in Colombia was 6%. Comorbidities and concomitant drugs are risk factors for drug-induced liver injury.spa
dc.format.extent7 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherAsociación Mexicana de Hepatologíaspa
dc.publisherElsevierspa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersionspa
dc.rightsinfo:eu-repo/semantics/openAccessspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/*
dc.titleEpidemiology of drug-induced liver injury in a University Hospital from Colombia: Updated RUCAM being used for prospective causality assessmentspa
dc.typeinfo:eu-repo/semantics/articlespa
dc.publisher.groupPromoción y Prevención Farmacéuticaspa
dc.identifier.doi10.1016/j.aohep.2018.11.008-
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2spa
dc.identifier.eissn2659-5982-
oaire.citationtitleAnnals of Hepatologyspa
oaire.citationstartpage501spa
oaire.citationendpage507spa
oaire.citationvolume18spa
oaire.citationissue3spa
dc.rights.creativecommonshttps://creativecommons.org/licenses/by-nc-nd/4.0/spa
oaire.fundernameUniversidad de Antioquia. Vicerrectoría de investigación. Comité para el Desarrollo de la Investigación - CODIspa
dc.publisher.placeCiudad de México, Méxicospa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa
dc.type.redcolhttps://purl.org/redcol/resource_type/ARTspa
dc.type.localArtículo de investigaciónspa
dc.subject.decsAnciano-
dc.subject.decsAged-
dc.subject.decsAnciano de 80 o más Años-
dc.subject.decsAged, 80 and over-
dc.subject.decsAlanina Transaminasa - metabolismo-
dc.subject.decsAlanine Transaminase - metabolism-
dc.subject.decsFosfatasa Alcalina - metabolismo-
dc.subject.decsAlkaline Phosphatase - metabolism-
dc.subject.decsBiomarcadores - metabolismo-
dc.subject.decsBiomarkers - metabolism-
dc.subject.decsEnfermedad Hepática Inducida por Sustancias y Drogas - diagnóstico-
dc.subject.decsChemical and Drug Induced Liver Injury - diagnosis-
dc.subject.decsEnfermedad Hepática Inducida por Sustancias y Drogas - epidemiología-
dc.subject.decsChemical and Drug Induced Liver Injury - epidemiology-
dc.subject.decsColombia - epidemiología-
dc.subject.decsColombia - epidemiology-
dc.subject.decsEstudios de Seguimiento-
dc.subject.decsFollow-Up Studies-
dc.subject.decsHospitalización - estadística & datos numéricos-
dc.subject.decsHospitalization - statistics & numerical data-
dc.subject.decsHospitales Universitarios - estadística & datos numéricos-
dc.subject.decsHospitals, University - statistics & numerical data-
dc.subject.decsIncidencia-
dc.subject.decsIncidence-
dc.subject.decsHígado-
dc.subject.decsLiver-
dc.subject.decsPruebas de Función Hepática-
dc.subject.decsLiver Function Tests-
dc.subject.decsPersona de Mediana Edad-
dc.subject.decsMiddle Aged-
dc.subject.decsPronóstico-
dc.subject.decsPrognosis-
dc.subject.decsEstudios Prospectivos-
dc.subject.decsProspective Studies-
dc.subject.decsMedición de Riesgo - métodos-
dc.subject.decsRisk Assessment - methods-
dc.subject.decsFactores de Riesgo-
dc.subject.decsRisk Factors-
dc.subject.decsAdulto Joven-
dc.subject.decsYoung Adult-
dc.description.researchgroupidCOL0074661spa
oaire.awardnumberConvocatorias de Sostenibilidad 2018–2019spa
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D000368-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D000369-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D000410-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D000469-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D015415-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D056486-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D003105-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D005500-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D006760-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D006785-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D015994-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D008099-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D008111-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D008875-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D011379-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D011446-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D018570-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D012307-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D055815-
dc.relation.ispartofjournalabbrevAnn. Hepatol.spa
oaire.funderidentifier.rorRoR:03bp5hc83-
Aparece en las colecciones: Artículos de Revista en Farmacéutica y Alimentarias

Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
AmarilesPedro_2019_Epidemiology_Drug-Induced.pdfArtículo de investigación868.4 kBAdobe PDFVisualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons